U.S. Device Start-Up Companies Move Rapidly, Efficiently and Safely Into Early First-In-Man Uses

Encinitas, CA, March 25, 2011 --(PR.com)-- acroMIS, a consulting company focused on first-in-man clinicals outside the U.S., extends an offer for initial consultation sessions in Chicago, from March 26 to March 28, 2011, in conjunction with the SIR Annual Scientific Meeting on interventional radiology, interventional oncology, peripheral arterial disease, venous disease, interventional neuroradiology and women’s health, with a continued focus on patient and disease management.

In addition, acroMIS extends its consultation sessions in San Antonio, Texas, from March 31 to April 2, 2011 in conjunction with the SAGES Annual Meeting, the largest national society of general surgeons providing up-to-date information in the fields of general, gastrointestinal, endoscopic, and minimally invasive surgery.

U.S. device executives who want to move rapidly, efficiently and safely into early first-in-man uses at selected European surgical centers, are invited to contact Haio Fauser at acroMIS for more details on the time and location for the workshop sessions. The expected outcome is a better understanding of the process for gaining reimbursement registration and initial European clinical experience in key EU countries.

All participants will have access to a white paper containing detailed information on how U.S. medical device startups can benefit from early clinical uses in Europe. The first part of the paper is titled, "New European Markets Can Bring Tangible Value to U.S. Device Companies," and describes the strategy for the implementation of early clinical uses in Europe. The second part is titled, "Free Movement Of U.S. Devices Within The European Market," and focuses on how to implement European CE marking requirements. The third part is titled, "European In-country Opportunity Assessment: Commercial Implementation and Business Development of U.S. Medical Innovation," and focuses on the pathway to early clinical uses and commercial success in Europe.

"The white paper is written as a How-To Manual," says Haio Fauser, managing director and co-founder of acroMIS. "For many companies with innovative technology, early clinical uses outside of the U.S. replace the perception of a product’s performance characteristics with an actual clinical experience."

About the author:
Haio Fauser’s professional career comprises over two decades of executive experience in the medical device industry with much of it directly focused on the development and commercialization of new device technologies and device-based therapies. To obtain a copy of the above mentioned white paper contact acroMIS at (650) 336-8641 or send an email to info@acroMIS.com.

###